Recent randomized, controlled trials suggest that B-cell-depletion therapy with rituximab effectively induces remission in anti-neutrophil-cytoplasmic-antibody-associated vasculitis but is ineffective in patients with lupus nephritis or nonrenal systemic lupus erythematosus with moderate-to-severe disease activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Furie, R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. [online], (2009).
Furie, R. et al. Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial. Arthritis Rheum. [online], (2009).
Merrill, J. T. et al. Flare assessment in systemic lupus erythematosus (SLE) patients treated with rituximab in the phase II/III EXPLORER trial. Arthritis Rheum. [online], (2009).
Merrill, J. T. et al. Treatment of systemic lupus erythematosus (SLE) with rituximab: 78-week safety data from the phase II/II EXPLORER trial. Arthritis Rheum. [online], (2009).
Stone, J. H. et al. Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE). Arthritis Rheum. [online], (2009).
Bosch, X., Guilabert, A., Espinosa, G. & Mirapeix, E. Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol. 29, 280–289 (2008).
Walsh, M. & Jayne, D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 72, 676–682 (2007).
Ng, K. P. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 66, 1259–1262 (2007).
Favas, C. & Isenberg, D. A. B-cell-depletion therapy in SLE—what are the current prospects for its acceptance? Nat. Rev. Rheumatol. 5, 711–716 (2009).
John Looney, R., Anolik, J. & Sanz, I. A perspective on B-cell-targeting therapy for SLE. Mod. Rheumatol. doi: 10.1007/s10165-009-0213-x.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Bosch, X. Rituximab in ANCA vasculitis and lupus: bittersweet results. Nat Rev Nephrol 6, 137–139 (2010). https://doi.org/10.1038/nrneph.2010.13
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.13
This article is cited by
-
Intrarenal production of B-cell survival factors in human lupus nephritis
Modern Pathology (2011)
-
Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians
Clinical and Experimental Nephrology (2011)
